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Abstract
Metastases are the major cause of death from melanoma, a skin cancer which has the fastest rising
incidence of any malignancy in the Western world. Molecular pathways that drive melanoblast
migration in development are believed to underpin the movement and ultimately the metastasis of
melanoma. Here we show that mice lacking P-Rex1, a Rac-specific Rho GTPase guanine
nucleotide exchange factor (GEF), have a melanoblast migration defect during development
evidenced by a white belly. Moreover, these P-Rex1−/− mice are resistant to metastasis when
crossed to a murine model of melanoma. Mechanistically, this is associated with P-Rex1 driving
invasion in a Rac-dependent manner. P-Rex1 is elevated in the great majority of human melanoma
cell lines as well as tumor tissue. We conclude that P-Rex1 plays an important role in melanoblast
migration and cancer progression to metastasis in mice and humans.
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Melanoma is an aggressive skin cancer characterized by its resistance to chemotherapy. Its
incidence has doubled over the past two decades in the Western world. Patients who have
primary melanomas with a Breslow thickness >4mm have a dramatically increased
incidence of metastasis and reduced survival1. Progression to melanoma is driven primarily
by oncogenic mutations of BRAF (50–60%) or NRAS (15–30%)2–4, but must be
accompanied by further genetic and epigenetic changes in gene expression, most commonly
the loss of tumour suppressors p16INK4A or PTEN5,6. Present treatments with conventional
chemotherapies have had no impact on overall survival, with the BrafV600E-targeted therapy,
vemurafenib (PLX4032), recently giving cause for encouragement7,8. However, there
remains a deficit of effective treatment strategies for other melanoma types, while treatment
resistance to vemurafenib has been reported in melanomas co-expressing NrasQ61K with
oncogenic BrafV600E 9,10.
PREX1 encodes the P-Rex1 Dbl family of Rho guanine nucleotide exchange factors
(RhoGEF). Rho family small GTPases comprise a major branch of the Ras superfamily of
small GTPases (e.g. RhoA, Rac1 and Cdc42)11. P-Rex1 is a Rac-specific GEF stimulated by
PI3K-stimulated phosphatidylinositol (3,4,5)-trisphosphate (PIP3) production and the beta-
gamma subunits of the heterotrimeric G proteins (Gßγ), both of which bind to P-Rex112–14.
It has also been identified as a transcriptional target of ERK signalling across a panel of
melanoma cell lines15. Rac, the main effector of P-Rex1 activity, is involved in the
induction of actin-mediated membrane ruffling and lamellipodia formation at the leading
edge of cell migration, and its aberrant activation has been implicated in tumor cell invasion
and metastasis16,17.
P-Rex1 has not previously been characterized in genetically modified animal models of
cancer that can genetically and pathologically recapitulate the human disease. Prior studies
using cancer cell lines have implicated a role in prostate, breast, and ovarian cancer18–21.
Here we demonstrate that P-Rex1 is necessary for migration of melanoblasts during mouse
development, it facilitates metastasis formation in an NrasQ61K-driven mouse model of
melanoma, and it is upregulated in human melanoma-derived cell lines and tissue.
RESULTS
P-Rex1-deficient mice have a white belly phenotype
We first investigated the in vivo relevance of P-Rex1 by further analyses of a P-Rex1−/−
mouse22. We identified a ‘white belly’ phenotype with 100% penetrance in P-Rex1−/− mice
on a pure C57BL6 background (Fig. 1a). The phenotype persisted when P-Rex1−/− mice
were crossed with Tyr::NrasQ61K/° transgenic mice (Tyr::NrasQ61K/°; P-Rex1−/−), a major
driver mutation in melanoma (Fig. 1a)23. Depigmentation affecting the feet was also
observed in Tyr::NrasQ61K/°; P-Rex1−/− mice (Fig. 1a). Tissue sections of bellies from P-
Rex1−/− and Tyr::NrasQ61K/°; P-Rex1−/− mice suggested no melanocytes were present
throughout the skin in the white belly area (Fig. 1b). Thus expression of NrasQ61K was not
able to overcome the ‘white belly’ induced by ablation of PREX1.
P-Rex1 deficiency impairs normal melanoblast migration
The belly, feet, and tail are the furthermost points of mouse melanoblast migration from the
neural crest during embryogenesis. In line with this and the role of P-Rex1 in activation of
Rac, we hypothesised that the areas of depigmentation in P-Rex1−/− mice predominantly
represented a defect of melanoblast migration during embryogenesis, rather than an
impaired proliferative capacity or inability to produce melanin pigment in adult
melanocytes. To test this hypothesis, we first ensured the expression of PREX1 in
melanoblasts (Fig. 2a).
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To address whether melanoblast number or migratory behaviour was altered, we next
analysed P-Rex1−/− mice and Tyr::NrasQ61K/°; P-Rex1−/− mice which had been intercrossed
to mice carrying the DCT-lacZ transgene, a melanoblast reporter line24. Melanoblast sparing
of the feet and belly was apparent in both DCT-lacZ P-Rex1−/− and DCT-lacZ
Tyr::NrasQ61K/°; P-Rex1−/− mice at E15.5, excluding a defect in melanin production as a
cause for their depigmentation (Figs. 2b,c).
Using a melanoblast migration assay, which compared differences in distal melanoblast
migration at various points of development (Fig. 2d, Supplementary Fig. S1a), analysis of
E13.5 and E15.5 embryos showed a statistical difference in melanoblast migration between
DCT-lacZ P-Rex1−/− and DCT-lacZ P-Rex1+/+ mice (Fig. 2e, Supplementary Fig. S1b).
This was not overcome by NrasQ61K/° expression (Fig. 2f, Supplementary Fig. S1b).
Consistent with a migratory defect, melanoblasts on the flank of the DCT-lacZ P-Rex1−/−
mice had fewer protrusions than DCT-lacZ P-Rex1+/+ controls (Figs. 2g,h).
A melanoblast cell number assay at E13.5 showed no difference in cell numbers between
DCT-lacZ P-Rex1−/− mice and DCT-lacZ P-Rex1+/+ mice unless DCT-lacZ P-Rex1−/− was
intercrossed with Tyr::NrasQ61K/° (Supplementary Figs. S2a,b). There was however a small
but significant reduction of E15.5 cell numbers in DCT-lacZ P-Rex1−/− mice compared to
DCT-lacZ P-Rex1+/+, and DCT-lacZ Tyr::NrasQ61K/°; P-Rex1−/− mice compared to DCT-
lacZ Tyr::NrasQ61K/°; P-Rex1+/+ mice (Figs. 2i,j). This difference is likely to represent a
proliferative deficit in P-Rex1−/− melanoblasts: cell death was not observed in E15.5 whole
skin from P-Rex1+/+ or P-Rex1−/− mouse embryos, using a live ex vivo imaging technique
we have previously described (Supplementary Movies 1–3)25. Moreover, a significant
reduction in E15.5 cell numbers was again seen in P-Rex1−/− embryos compared to P-
Rex1+/+ controls using this technique (Supplementary Fig. S2c). Collectively, these results
would be consistent with previous reports of a role for Rac in cell cycle control, as well as
the proliferative defect observed when P-Rex1 was knocked down in breast cancer cell
lines21,26,27. They suggest that a small proliferative defect is preceded by a marked
migration defect in P-Rex1−/− mice, although further studies are required to definitively
elucidate a role for P-Rex1 in proliferation.
P-Rex1 deficiency impairs metastasis in a melanoma mouse model
The imprint of past migratory behaviour of neural crest derived melanocyte precursors has
been suggested to confer a propensity of primary melanomas to establish distant
metastases28–30. We therefore crossed P-Rex1−/− mice to a genetically modified model of
metastatic malignant melanoma, Tyr::NrasQ61K/°; INK4a−/− mice, to assess whether P-Rex1
may also be important for primary melanoma development and/or metastasis23.
Tyr::NrasQ61K/°; INK4a−/−; P-Rex1+/+ mice developed primary melanoma and metastasis
with a similar penetrance and latency to that previously described (Fig. 3a). IHC was carried
out on primary melanomas taken from P-Rex1+/+ and P-Rex1−/− mice to confirm P-Rex1
expression in tumors (Figs. 3b,c). 7/10 primary melanomas from P-Rex1+/+ mice showed
staining for P-Rex1, compared to 0/9 samples from P-Rex1−/− mice. All metastases from P-
Rex1+/+ mice displayed immunoreactivity for P-Rex1 similar to that of MelanA (11
samples; lung, liver, brain) (Fig. 3d).
Although Rac function has been shown to be required for primary squamous cell skin and
lung tumor development31,32, we observed no difference in incidence, latency, or tumor
burden of primary melanomas between Tyr::NrasQ61K/°; INK4a−/−; P-Rex1+/+ mice and
Tyr::NrasQ61K/°; INK4a−/−; P-Rex1−/− mice (Table 1; Figs. 3e,f). However, a highly
significant reduction in melanoma metastasis was observed in the Tyr::NrasQ61K/°;
INK4a−/−; P-Rex1−/− cohort, with the number of metastases in control Tyr::NrasQ61K/°;
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INK4a−/−; P-Rex1+/+ mice the same as previously reported (p=0.001; chi-square) (Table 1).
Tyr::NrasQ61K/o; INK4a−/−; P-Rex1−/− mice also had an improved overall survival (Fig. 3g).
These data are consistent with the mouse melanoblast data, suggesting that P-Rex1 is a
central component of migration and invasion.
Although we are unable to categorically exclude the possibility that our melanoma brain
lesions are not primary melanocytic neoplasms of the CNS, a significant reduction in
metastases was still seen when these lesions were excluded from our analysis (Table 1).
Clearly they at least invade the brain parenchyma from either a blood-borne metastasis or
the lepto-meningeal site of origin in primary CNS melanoma (Fig. 3d). In support of them
being genuine metastases, no NrasQ61K mutations were observed in a prior study of human
primary CNS melanoma33.
We next further explored the pro-metastatic role of endogenous P-Rex1 in melanoma by
deriving melanocyte cell lines from the early pup skin of Tyr::NrasQ61K/°; INK4a−/−; P-
Rex+/+ and Tyr::NrasQ61K/°; INK4a−/−; P-Rex1−/− mice. When injected via tail vein into
C57BL6 mice, 2/4 mice treated with Tyr::NrasQ61K/°; INK4a−/−; P-Rex1−/− melanocytes
were found to have metastases, compared with 5/5 mice who were treated with
Tyr::NrasQ61K/°; INK4a−/−; P-Rex+/+ cells (Supplementary Table S1; Supplementary Fig.
S3). A significant reduction in metastatic frequency was observed on histological analyses
of the cohort injected with Tyr::NrasQ61K/°; INK4a−/−; P-Rex1−/− melanocytes, with a clear
reduction in metastatic tumor burden also seen (Supplementary Figs. S3a,b). Moreover, we
observed a clear propensity of the Tyr::NrasQ61K/°; INK4a−/−; P-Rex+/+ cells to metastasise
to distant viscera (kidney, liver, heart, spleen), metastases that were not seen in the mice TV-
treated with Tyr::NrasQ61K/°; INK4a−/−; P-Rex1−/− cells (Supplementary Table S1;
Supplementary Figs. S3c-g). Collectively, these results suggested endogenous P-Rex1 can
facilitate frequency, growth and organ spread of metastases in melanoma from the
intravasation stage of the metastatic cascade.
These data in genetically modified models of cancer were also supported by analyses of
immuno-deficient mice which were injected subcutaneously with a number of different
human melanoma-derived cell lines (Supplementary Figs. S4a,b; Supplementary Table S2).
In total, 18/24 cell lines developed tumors following injection, with 4/24 also forming
metastases. Quantitative RT-PCR analysis revealed that, of the cell lines with P-Rex1
mRNA levels above the median (‘high’ P-Rex1), nearly all went on to develop tumors in
immuno-deficient mice (Supplementary Figs. S4a). This included all mice that developed
metastases, and notably, the two NrasQ61K and BrafV600E cell lines with the highest P-Rex1
mRNA levels both developed metastases. Statistical evaluation of these results confirmed
high P-Rex1 was 100% statistically sensitive for detecting those nude mice that developed
metastases (Supplementary Table S3) (p=0.005; chi-square test). P-Rex1 expression was
highest in cell lines that form metastases after averaging P-Rex1 levels in cell lines that
formed no tumors, tumors, or metastases (Supplementary Figs. S4b). The lowest expression
occurred in those cell lines that don’t form tumors in immuno-deficient mice
(Supplementary Figs. S4b).
P-Rex1 is upregulated and drives invasion in human melanoma
To test the relevance of our data to human melanomagenesis, we first examined the
expression of P-Rex1 in established human melanoma cell lines derived from primary or
metastatic disease. Compared to normal human melanocytes (NHM), there was marked P-
Rex1 overexpression in nearly all of the cell lines (Fig. 4a). Moreover, the 3 cell lines with
clearly the highest P-Rex1 expression (CHL1, SK-Mel119, Mel224) were all derived from a
metastatic source (Supplementary Table S4), supporting our above analysis that showed
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high P-Rex1 mRNA was sensitive for the development of metastases in immune-deficient
mice (Supplementary Fig. S4).
We next assessed whether increased P-Rex1 activity in humans is also related to melanoma
progression: this possibility was raised by both the sensitivity of high P-Rex1 mRNA for
nude mouse metastasis development and the increased expression of P-Rex1 observed in
melanoma-derived cell lines compared to normal melanocytes. IHC for P-Rex1 was
performed on human tissue specimens from skin and melanoma: although P-Rex1
expression was not detectable in melanocytes in normal skin (3 out of 3 specimens), we
consistently detected it in biopsies of primary melanomas (112 out of 141 specimens) and
melanoma lymph node metastases (8 out of 9 specimens) (Fig. 4b; Supplementary Figure
S5). These data provided further evidence of a role for P-Rex1 in human melanoma
progression, and were consistent with our prior findings in mice.
One potential way P-Rex1 could drive progression and metastatic spread is through an
increased invasive capacity conferred by its RacGEF activity. To examine this, we knocked
down endogenous P-Rex1 in the CHL1 human melanoma cell line where P-Rex1 was
upregulated in Figure 4a. Consistently we observed that 3D matrigel invasion was
diminished following knockdown of endogenous P-Rex1 (Fig. 4c-e). This result was also
reproducible in the WM793 human melanoma cell line used in our RT-PCR data
(Supplementary Figs. S6a-c). As P-Rex1 is overexpressed in the majority of human
melanoma cell lines, we used the previously described melanocyte cell line derived from
early pup skin of Tyr::NrasQ61K/°; INK4a−/−; P-Rex1−/− mice to examine invasion in a cell
line where P-Rex1 is not endogenously expressed. These P-Rex1−/− cell lines, which were
genetically manipulated to over-express empty vector (‘pLHCX’), failed to invade in 3D
matrigel and organotypic assays unless they were re-constituted to express ectopic levels of
P-Rex1 (‘P-Rex1’) (Figs. 4f-i). Expression of ectopic levels of GEF-dead P-Rex1 (‘P-Rex1
GD’) failed to phenocopy the invasive phenotype of cells with re-constituted wild-type P-
Rex1, confirming the RacGEF activity of P-Rex1 as a downstream mechanism (Figs. 4f-i).
Interestingly, ectopic expression of another RacGEF described in melanoma, TIAM1, also
failed to phenocopy the invasion seen with P-Rex1 expression (Figs. 4f-h)34. These results
showed the RacGEF activity of P-Rex1 may have a unique role amongst RacGEFs: it
functions as a vital component of invasion for cells of the melanocyte lineage, a mechanism
by which it can drive melanoma progression and metastases.
DISCUSSION
Here we evaluated the role of a Rac-specific Rho GTPase GEF, P-Rex1, for the first time in
a genetically modified animal model of cancer. In particular we have examined its role in
melanoma progression, invasion and metastasis. First, we showed P-Rex1 has a role in
progression with our human cell line and IHC analysis showing P-Rex1 upregulation in
tumor compared to normal human melanocytes. Second, matrigel and organotypic invasion
assays confirmed P-Rex1 is a key component of invasion in both humans and mice,
channeled through its RacGEF activity. Finally and most importantly, we have determined
that genetic ablation of PREX1 impairs melanoma metastases in Tyr::NrasQ61K INK4a−/−
mice. Taken together, these results confirm that P-Rex1 upregulation is an important
component of melanoma progression, invasion and metastatic signaling, supporting the
value of pharmacological inhibition of P-Rex1 activation of Rac for treatment of metastatic
or high risk primary melanomas.
Mechanistic experiments in our study have highlighted the key similarities between the
molecular machinery involved in the movement of melanoblasts and that of metastatic
melanoma cells. Genetic ablation of PREX1 impaired migration of melanoblasts, evidenced
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by a ‘white belly’ phenotype that reflected the diminished metastases seen in Tyr::NrasQ61K
INK4a−/− mice. A potential pathophysiological link between incidence of metastases
therefore fits with the physiological role of P-Rex1 seen in melanoblast migration.
Moreover, the predominant role of P-Rex1 in invasion and migration is reflected by its
presence in motile melanoblasts and its upregulation in metastatic melanoma cell lines.
Other studies have previously suggested a role for P-Rex1 in prostate, breast, and ovarian
cancer18–21, with key similarities existing between our study and that of Sosa et al in
particular. Notably, this report identified P-Rex1 as having particular relevance to the
specific ER+ (+/− ErbB2) subset of breast tumors. One key area to focus on next will be to
assess whether the in vivo tumorigenic effects of P-Rex1 are specific to melanomas driven
by oncogenic Nras, or reproducible in BrafV600E-driven tumours: this is a clear possibility
given the identification of P-Rex1 as a transcriptional target of ERK signaling in
melanoma15. These prior P-Rex1 cancer studies have also shown an effect on both primary
tumor growth and lymph node metastases using xenotransplantation of human cancer cell
lines into immunodeficient mice. However this technique often fails to recapitulate the
characteristics of the original tumor they are meant to represent, and their use for
informative studies of novel cancer target validation has become increasingly
contentious35–37. A key advance in our study is therefore the characterization of P-Rex1 in
animal models of cancer which recapitulate the common human genetics of the disease.
Strategies for inhibiting RAS have long been a therapeutic challenge9. Our findings suggest
that targeting P-Rex1 signaling might have great relevance to tumors driven or co-driven by
oncogenic RAS, with potential benefits extending to all melanomas10. There is limited but
growing evidence that RhoGEFs are tractable targets for the development of small molecule
inhibitors17. The lack of P-Rex1 expression in most other normal human cell types offers a
clear therapeutic window and basis for selective cytotoxicity14,37.
Here we have identified P-Rex1 as a novel anticancer target in melanoma. Our experiments
provide stringent preclinical validation of P-Rex1 in cancer using informative genetically
defined mouse models that recapitulate common human mutations. Together with recent
observations in other cancers18–21, we suggest that P-Rex1 is an important therapeutic target
for the treatment of a diverse spectrum of human cancers.
METHODS
Embryo analysis and β-galactosidase (lacZ) staining
Time of gestation was calculated using noon on the day of detection of a vaginal plug as
E0.5, but also noting and comparing the external appearance of the embryo. Embryos were
dissected at E15.5 then fixed in 0.25% glutaraldehyde at 4°C for 45m on a rolling platform.
Embryos washed in PBS at 4°C for 15m on a rolling platform, detergent washed (2 mM
MgCL2, 0.01% Na-deoxycholate, 0.02% NP-40 in PBS) at room temperature ×3 (30 min, 15
min × 2). β-galactosidase substrate (1M MgCl2, 0.02% NP-40, 0.01% Na-deoxycholate,
0.04% X-Gal, 5 mM K3Fe(CN)6, 5 mM K4Fe(CN)6) then added to the embryos which were
incubated in darkness overnight. Embryos post-fixed in 4% paraformaldehyde for 2h at 4°C.
For cell number assays, the area used for quantification of cell numbers represented the most
proximal point of melanoblast migration from the neural crest which could be accurately
assayed. Counting melanoblasts in more distal regions would have introduced a migrational
component to the assay which we aimed to avoid.
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Mouse treatments, ageing and survival cohorts
80 Tyr::NrasQ61K/°; INK4a−/− and 10 C57BL6 mice were monitored for up to 18 months for
development of melanoma and signs of metastasis. All mice checked 3×weekly for
development of malignant melanoma or any other pathology. Endpoint criteria were
melanomas ≥ 15mm, ulcerating melanomas, cachexia, significant weight loss, or weakness
and inactivity. Upon meeting these criteria, mice were euthanized. Mice were examined for
the presence of frank metastasis upon dissection, but also visualisation of haematoxylin and
eosin (H&E) stained sections for further identification of microscopic metastases. Organs/
tumors were removed and fixed in 10% buffered formalin overnight at room temperature.
Fixed tissues were paraffin embedded and 5mm sections placed on sialynated/poly-L-lysine
slides for immunohistochemical analysis. Lymph node metastases were not included in this
analysis due to difficulty in distinguishing them from normal melanocyte populations that
can be found in lymphoid tissue.
For TV-injections into C57BL6 mice, cultured cells maintained in antibiotic-free media for
1 week prior to injection. Cells were detached with trypsin, then blocked through suspension
in complete culture media supplemented with 10 % foetal bovine serum. Cells subjected to
two rounds of washing, involving centrifugation at 100gs for 5m followed by resuspension
in 1 × Hanks’ Balanced Salt Solution (HBSS). Cells finally resuspended in HBSS to a
concentration of 1 × 107 cells/ml and TV-injected at 1 × 106 cells/animal in a volume of
100µl.
Immunohistochemistry
For P-Rex1, serial sections were unmasked in 10 mM citric acid, pH 6.0 with boiling for
30m. Remaining steps were carried out with Thermo ScientificUltraVision LP Detection
System (Thermo Fischer Scientific). Primary antibody was incubated in the presence of 5%
normal goat serum (Dako). Antigens were developed with Vector Red Alkaline Phosphatase
Substrate Kit (Vector Labs). The following antibody dilutions were used: P-Rex1, 1:100;
MelanA, 1:100. ‘Positive’ staining refers to any level of staining visualized.
Antibodies
Rabbit polyclonal raised against human P-Rex1 (HPA001927) and mouse monoclonal
specific to β-actin (clone AC-15, A1978) were obtained from Sigma-Aldrich limited. Mouse
monoclonal specific to Melan-A (clones DT101 + BC199, ab731) was obtained from Abcam
Ltd.
Human Tissues
A tissue microarray (TMA) was performed on archival paraffin patient samples from St.
Vincent’s University Hospital, Dublin, Ireland. Quadruplicate cores from 141 consecutive
melanoma patients (1994–2007) were used to construct the TMA. Further samples were
received from Radboud University Medical Center, Nijmegen, Netherlands. All patient
specimens were used in accordance with institutional and national policies at the respective
locations.
Statistical analyses
Statistical Analyses in mice were carried out using Minitab® version 15 for Windows. Cell
migration, invasion, and cell number differences determined using Mann-Whitney test.
Distinction of metastasis and primary melanoma incidence was achieved using chi-square
testing. Survival differences were determined with log-rank testing. All p values considered
significant at p = <0.05. All appropriate value sets tested for normality using a Kolmogorov-
Smirnoff normality test.
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Cell culture
Normal human melanocytes (NHM) were maintained in Mln254 medium (M-254-500,
Cascade Biologics) supplemented with Human Melanocyte Growth Serum (S-002-5,
Cascade Biologics) and penicillin/streptomycin at 100 U/ml. Mel224, Mel505, SK-Mel 2, 5,
23, 119, 147 and 187, CHL-1, A375 and WM266.4 were maintained in Dulbecco’s
Modified Eagle Medium supplemented with 10% foetal calf serum, L-glutamine at 200µM
and penicillin/streptomycin at 100 U/ml. SBCL2, Lu1205, WM852, MeWo, Dauv-1,
Gerlach, 888mel, 501mel, MNT-1, WM 35, 278, 793, 902b, 1552c and 1789 were
maintained in RPMI 1640 supplemented with 10% foetal calf serum and penicillin/
streptomycin at 100U/ml.
For melanocyte isolation from mice, pup skin was dissected at P2 then placed in ice cold
PBS. Quickly it was cut into pieces and incubated in 1.5ml of collagenase type 1 and 2 at
37°C, 5% CO2 for approximately 25–50m. Contents transferred into 10ml wash buffer
(1×HBSS, 1mM CaCl2, 0.005% DNase) and centrifuged at 200gs for 5m at room
temperature. Sample resuspended in 2ml dissociation buffer, placed in small Petri dish and
incubated at 37°C, 5% CO2 for 10m. Thereafter, sample put through an 18g then 20g needle
and transferred into 10ml wash buffer for 10m. Supernatant centrifuged at 200gs for 5m at
room temp, pellet resuspended in 2ml PBS, then re-centrifuged at 200gs for 5m.
Resuspended and maintained in RPMI 1640 medium supplemented with 10% foetal calf
serum, L-glutamine at 200µM, and penicillin/streptomycin at 100 U/ml.
siRNA treatments and RacGEF constructs
Stable cell lines expressing Myc-epitope tagged human P-Rex1 were generated by retroviral
infection using the modified Retro-X retroviral expression system (Clontech). An Hpa I
restriction site, followed by Kozak consensus translation initiation site was introduced to the
5’ end of the coding sequence of myc-P-Rex113, myc-P-Rex1 GEF-dead13, or myc-Tiam1
by PCR (5’ GTTAACCACCATGGAGCAGAAGCTGATC 3’), with a Cla I restriction site
introduced to the 3’ end in the same reaction (P-Rex1/P-Rex1 GEF-dead - 5’
CCATCGATTCAGAGGTCCCCATCCACCGG 3’), with pCMV-P-Rex1, pCMV-P-Rex1
GEF-dead or pcDNA3.1-myc-Tiam1 used as template. In each case, the Hpa I-Cla I DNA
fragments produced were subcloned into Hpa I and Cla I sites of the pLHCX retroviral
expression vector. High-titre, replication-incompetent retroviral particles encoding the RNA
of interest were produced in the Phoenix Ampho packaging line (Orbigen), for human target
cells, and the Phoenix Eco packaging line (Orbigen) for murine target cells. Subsequent
infection of target lines resulted in transfer of the coding region of interest, along with a
selectable marker. Pooled cell lines stably expressing the construct of interest were isolated
by selection with hygromycin-B (500 µg/ml) over multiple passages. Control lines were
infected with retroviral particles expressing an empty pLHCX control vector transcript, and
subjected to an identical selection procedure. Expression of the ectopically-introduced
proteins of interest was determined by western blot and immunodetection with both epitope-
tag specific and protein specific primary antibodies.
Transient knockdown of target proteins was achieved through consecutive rounds of
liposome-mediated transfection with the appropriate siRNA oligonucleotides, 48 h apart.
Liposomal transfection reagent (301702, HiPerFect), non-targeting control oligonucleotides
(1027281, AllStars Negative Control) and P-Rex1 specific oligonucleotides (SI00692405,
Hs_PREX1_3; SI03144449, Hs_PREX1_5; SI03246383, Hs_PREX1_6) obtained from
Qiagen Ltd.
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Invasion assays
For inverted Matrigel invasion assays38, Matrigel protein matrix (BD bioscience) was
allowed to polymerise in Transwell permeable inserts (Corning Ltd.) over a period of 60m at
37°C. Inserts were inverted, and cells seeded directly onto the filter surface in complete
growth medium. Cells then allowed to adhere over a period of 3h at 37°C, after which both
non-adherent cells and residual growth medium were removed with 3×washes in appropriate
serum-free medium. Finally, inserts were placed in serum-free tissue culture medium
(containing 10% foetal calf serum) above the Matrigel matrix to act as a chemoattractant. In
the case of siRNA-mediated transient knockdown experiments, invasion assays were
prepared 24 hours after the second round of lipofection. At 72h post-seeding, invasive cells
which had entered Matrigel were stained with the fluorescent live-cell dye Calcein-AM, and
visualised through confocal microscopy of optical sections obtained in the z-plane at 15 µm
intervals. Quantification was with the Area Calculator plugin for ImageJ
(http://rsbweb.nih.gov/ij/).
For organotypic invasion assays39, ~7.5×104/ml primary human fibroblasts were embedded
in a three-dimensional matrix of rat tail collagen I. Rat tail tendon collagen solution was
prepared by the extraction of tendons with 0.5 M acetic acid to a concentration of ~2 mg/ml.
Detached, polymerized matrix (2.5 ml) in 35mm petri dishes was allowed to contract for
approximately 6 days in complete media (DMEM, supplemented with 10% FCS, Invitrogen)
until the fibroblasts had contracted the matrix to ~1.5 cm diameter. Subsequently,
Tyr::NrasQ61K/°; INK4a−/−; P-Rex1−/− melanocytes, stably expressing either control vector,
human P-Rex1 or a GEF-dead mutant of human P-Rex1, were seeded onto the prepared
matrix in complete media (4 × 104 cells per assay) and allowed to grow to confluence for 5
days. The matrix was then mounted on a metal grid and raised to the air/liquid interface
resulting in the matrix being fed from below with complete media that was changed every 2
days. After 15 days, the cultures were fixed with 4% paraformaldehyde and processed by
standard methods for haematoxylin and eosin staining.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
P-Rex1-deficient mice have a ‘white belly’ phenotype (a) Belly and feet of P-Rex1+/+ and
P-Rex1−/− mice in combination with both Nras+/+ and NrasQ61K/° transgenic modification.
(b) Photomicrographs (H&E) of belly skin from the four genotypes represented in (a).
Normal melanocyte situation in a C57BL6 mouse is in the hair follicles (black arrows).
Melanocytes and deposition of melanin in the dermis (red arrow) and adipose tissue (red
arrowheads) is seen in NrasQ61K/° mice. Scale bars = 100µm.
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Figure 2.
P-Rex1−/− mice have a defect in melanoblast migration. (a) RT-PCR of P-Rex1 mRNA in
E14.5 embryo skin following FACS selection of cells enriched for melanoblasts (YFP+)
compared to the rest of the embryo skin (YFP-). Tyrosinase and Dct controls confirm
melanoblast enrichment. (b) E15.5 representative pictures comparing melanoblast migration
to the belly in X-gal stained embryos. Scale bars = 500µm. (c) Comparison of melanoblast
migration along forepaw in X-gal stained embryos at E15.5. A migratory deficit is evident in
both P-Rex1−/− (with either Nras+/+ or NrasQ61K/°) embryos. Scale bars = 500µm. (d)
Schematic picture detailing quantification of melanoblast migration in the forepaw at E15.5.
Levels 1 to 6 from top to bottom represent areas of 500µm × 500µm. Melanoblasts counted
at each level and numbers compared between genotypes. (e,f) Comparison of melanoblast
migration between P-Rex1+/+ (blue bars) and P-Rex1−/− (red bars) mice at levels 1 to 6 (as
detailed in (d)). Upper panel (e) represents Nras+/+ embryos (*p=0.01/0.02, Levels 2/3;
Mann-Whitney test, n=5), lower panel (f) represents NrasQ61K/° embryos
(*p=0.02/0.02/0.01, Levels 1/2/3; Mann-Whitney test, n=5) (All box and whiskers plots:
boxes represent 25th-75th percentiles of given value, lines represent median values) (g)
Representative pictures at E15.5 of melanoblast morphology and protrusions (red arrows) on
the flank of X-gal stained embryos. Scale bars = 100µm. (h) Quantification and comparison
of percentage of cells with 1+ protrusions: P-Rex1+/+ (N WT, blue bars) and P-Rex1−/− mice
(N HOM, red bars) (left hand panel; *p=0.05, Mann-Whitney; n=4); and Tyr::NrasQ61K/°; P-
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Rex1+/+ (Y WT, blue bars) and Tyr::NrasQ61K/°; P-Rex1−/− (Y HOM, red bars) mice (right
hand panel; *p=0.03; Mann-Whitney, n=4). (i) Schematic picture detailing quantification of
melanoblast cell numbers at E15.5. Areas represented: 1mm × 3mm. (j) Comparison of
E15.5 melanoblast numbers between P-Rex1+/+ (N WT, blue bars) and P-Rex1−/− (N HOM,
red bars) mice (left hand panel), and also between Tyr::NrasQ61K/°; P-Rex1+/+ (Y WT, blue
bars) and Tyr::NrasQ61K/°; P-Rex1−/− (Y HOM, red bars) mice (right hand panel). (left
panel: *p =0.01; right panel: *p =0.01; Mann-Whitney test, n=5)
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Figure 3.
P-Rex1−/− mice have significantly reduced metastases in a Tyr::NrasQ61K/°; INK4a−/−
murine melanoma model (a) Primary and metastatic melanomas arising in Tyr::NrasQ61K/°;
INK4a−/− transgenic mice. Red arrowhead: pigmented primary skin melanoma; White
arrowheads: multiple pigmented lung metastases; Red arrow: pigmented liver metastasis;
White arrow: large pigmented brain lesion (b) MelanA and P-Rex1 immunohistochemical
expression in primary melanomas of P-Rex1+/+ mice. Varying levels of P-Rex1 expression
can be seen in mouse melanomas (pink staining). n=10. (c) MelanA and P-Rex1
immunohistochemical expression in primary melanomas of P-Rex1−/− mice. No P-Rex1
expression was observed in melanomas from these mice. n=9. (d) MelanA and P-Rex1
immunohistochemical expression in melanoma metastases from P-Rex1+/+ control mice.
Upper four panels show expression in brain lesions, while lower four panels show
expression in lung metastases (pink staining). n=11. (e) Comparison of primary tumor
burden between Tyr::NrasQ61K/°; INK4a−/−; P-Rex1+/+ (blue bar) and Tyr::NrasQ61K/°;
INK4a−/−; P-Rex1−/− (red bar) mice (p=0.43, Mann-Whitney, n=29; small asterisks
represent outlying data) (Box and whiskers plot: box represent 25th-75th percentile of given
value, line represents median value). (f) Kaplan-Meier analysis of primary melanoma
latency between Tyr::NrasQ61K/°; INK4a−/−; P-Rex1+/+ (black line, n=27) and
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Tyr::NrasQ61K/°; INK4a−/−; P-Rex1−/− (red line, n=18) cohorts (p=0.156, log-rank test). (g)
Kaplan-Meier curves detailing significant improvement in survival of Tyr::NrasQ61K/°;
INK4a−/−; P-Rex1−/− cohort (red line) compared to Tyr::NrasQ61K/°; INK4a−/−; P-Rex1+/+
cohort (black line) (*p=0.017, log-rank test, n=30 for each cohort).
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Figure 4.
P-Rex1 is upregulated in human melanoma where it drives invasion through its RacGEF
activity (a) Western blots illustrating endogenous expression of P-Rex1 in a panel of human
melanoma derived cell lines. Cell lines with driver mutations in NRAS and BRAF are
represented, along with cell lines that are WT for both. NHM = normal human melanocytes.
(b) P-Rex1 expression increases with more aggressive disease. Photomicrographs of human
tissue specimens of normal skin, primary and metastatic melanoma, immunohistochemically
labelled against P-Rex1 or the melanocyte marker melanA. LN = lymph node. Scale bars =
90µm. (c) Silencing P-Rex1 by siRNA as shown by western blot analysis. A mock
transfection and scramble siRNA were used as controls. (d) Comparison of representative
matrigel invasion assays of CHL1 human melanoma cell lines treated with control or P-
Rex1 specific siRNA oligonucleotides. (e) Quantification of cells invading beyond 45µm in
matrigel invasion assays of CHL1 human melanoma cell lines treated with control
(‘siControl’) vs P-Rex1 (‘siP-Rex1’) specific siRNA oligonucleotides. (*p=0.005, Mann-
Whitney test; n=3; error bars = +/− standard error of mean (SEM). (f) Westen blot
confirming relative expression of ‘P-Rex1’, ‘P-Rex1 GD’, and ‘Tiam1’ cells is well
matched. (g) Representative matrigel invasion assays comparing melanocytes derived from
early pup skin of Tyr::NrasQ61K/°; INK4a−/−; P-Rex1−/− mice and genetically modified to
over-express P-Rex1 (‘P-Rex1’), empty vector (‘pLHCX’), GEF-dead P-Rex1 (‘P-Rex1
GD’), or Tiam1 (‘Tiam1’) (h) Left panel: quantification of cells invading beyond 45µm in
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matrigel invasion assays of pLHCX vs P-Rex1 vs P-Rex1 GD cells (*p=<0.0001 for both
comparisons, Mann-Whitney test; n=3). Right panel: quantification of cells invading beyond
45µm in matrigel invasion assays of pLHCX vs P-Rex1 vs Tiam1 cells (*p=<0.0001 for
both comparisons, Mann-Whitney test; n=3; error bars for both panels = +/− standard error
of mean (SEM). (i) Representative organotypic invasion assays comparing Tyr::NrasQ61K/°;
INK4a−/−; P-Rex1−/− parental melanocytes genetically manipulated to over-express wild-
type P-Rex1 (‘P-Rex1’), empty vector (‘pLHCX’) and GEF-dead P-Rex1 (‘P-Rex1 GD’)
(n=3; Scale bars = 90µm).
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Table 1
P-Rex1−/− dramatically reduces incidence of metastasis in an Tyr::NrasQ61K/°; INK4a−/− transgenic murine
melanoma model. Table detailing numbers of mice within both Tyr::NrasQ61K/°; INK4a−/−; P-Rex1+/+ and
Tyr::NrasQ61K/°; INK4a−/−; P-Rex1−/− cohorts suffering from primary and metastatic melanoma (chi-square
test). Metastatic sites other than brain for Tyr::NrasQ61K/°; INK4a−/−; P-Rex1+/+ cohort were lungs (4 mice),
liver (3 mice), peritoneum (1 mouse); Tyr::NrasQ61K/°; INK4a−/−; P-Rex1−/− metastasis was in lungs.
Genotypes Mice with Primary
Melanoma
Average
Age (days)
Mice with
Melanoma
Metastases
Mice with Melanoma
Metastases, Excluding Brain
Lesions
Tyr::NrasQ61K/°; INK4a−/−; P-Rex1+/+ 30/41 184 13/30 6/30
Tyr::NrasQ61K/°; INK4a−/−; P-Rex1−/− 30/42 211 1/30 1/30
p = 0.001 p = 0.044
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